Patents by Inventor Jennifer E. Ring

Jennifer E. Ring has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE
    Publication number: 20240000790
    Abstract: This invention relates to methods comprising administering a FAK inhibitor and an immunotherapeutic agent such as anti-PD-1 or anti-PD-L1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.
    Type: Application
    Filed: December 21, 2022
    Publication date: January 4, 2024
    Inventors: Jonathan A. Pachter, Jennifer E. Ring, David T. Weaver, Yan Wang
  • Therapeutic compositions, combinations, and methods of use
    Patent number: 11564927
    Abstract: This invention relates to methods comprising administering a FAK inhibitor and an immunotherapeutic agent such as anti-PD-1 or anti-PD-L1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: January 31, 2023
    Assignee: Verastem, Inc.
    Inventors: Jonathan A. Pachter, Jennifer E. Ring, David T. Weaver, Yan Wang
  • THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE
    Publication number: 20200330471
    Abstract: This invention relates to methods comprising administering a FAK inhibitor and an immunotherapeutic agent such as anti-PD-1 or anti-PD-L1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.
    Type: Application
    Filed: November 25, 2019
    Publication date: October 22, 2020
    Inventors: Jonathan A. Pachter, Jennifer E. Ring, David T. Weaver, Yan Wang
  • Therapeutic compositions, combinations, and methods of use
    Patent number: 10532056
    Abstract: This invention relates to methods comprising administering a FAK inhibitor and an immunotherapeutic agent such as anti-PD-1 or anti-PD-L1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: January 14, 2020
    Assignee: Verastem, Inc.
    Inventors: Jonathan A. Pachter, Jennifer E. Ring, David T. Weaver, Yan Wang
  • THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE
    Publication number: 20180177788
    Abstract: This invention relates to methods comprising administering a FAK inhibitor and an immunotherapeutic agent such as anti-PD-1 or anti-PD-L1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.
    Type: Application
    Filed: June 29, 2016
    Publication date: June 28, 2018
    Inventors: Jonathan A. Pachter, Jennifer E. Ring, David T. Weaver, Yan Wang
  • PRPK-TPRKB modulators and uses thereof
    Patent number: 9193989
    Abstract: The present invention provides methods of identifying an agent that modulates PRPK, TPRKB, OSGEP, LAGE3 and its homologs, PRPK/TPRKB complex, and/or KEOPS complex. The present invention also provides compositions of such agents and methods of treating a disease, disorder, or condition associated with PRPK, TPRKB, OSGEP, LAGE3 and its homologs family (CT antigens), PRPK/TPRKB complex, and/or KEOPS complex using such an agent or composition.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: November 24, 2015
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Eun Sun Park, Henry E. Pelish, Astrid S. Clarke, Grace L. Williams, Maria Paola Castaldi, Alexander Arefolov, Jennifer E. Ring, Matthew D. Shair, Randall W. King
  • PRPK-TPRKB MODULATORS AND USES THEREOF
    Publication number: 20110319277
    Abstract: The present invention provides methods of identifying an agent that modulates PRPK, TPRKB, OSGEP, LAGE3 and its homologs, PRPK/TPRKB complex, and/or KEOPS complex. The present invention also provides compositions of such agents and methods of treating a disease, disorder, or condition associated with PRPK, TPRKB, OSGEP, LAGE3 and its homologs family (CT antigens), PRPK/TPRKB complex, and/or KEOPS complex using such an agent or composition.
    Type: Application
    Filed: June 17, 2011
    Publication date: December 29, 2011
    Inventors: Eun Sun Park, Henry E. Pelish, Astrid S. Clarke, Grace L. Williams, Maria Paola Castaldi, Alexander Arefolov, Jennifer E. Ring, Matthew D. Shair, Randall W. King